ASCO 2025 – BioNTech’s latest Claudin6 effort falls short
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.